Melamed A, Rauh-Hain JA, Gockley AA, et al. - Findings indicate that administration of neoadjuvant chemotherapy as first-line therapy may be appropriate for many patients suffering from advanced-stage ovarian cancer.

• This is a comparative effectiveness research study.

• Participants were 39,299 patients with stage IIIC and IV epithelial ovarian cancer treated in 664 cancer programs, including programs that increased or marginally increased the use of neoadjuvant chemotherapy from January 2004 to December 2015.

• Greater improvements in short-term mortality were provided by programs that markedly increased administration of neoadjuvant chemotherapy vs programs with low use of neoadjuvant chemotherapy.

• Improvements in median overall survival were similar between both programs.